Global Pulmonary Drugs Market: Industry Analysis and Forecast (2019-2026) – by Drug Class, Application, Distribution Channel, and Region

Global Pulmonary Drugs Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period. Global Pulmonary Drugs Market To know about the Research Methodology :- Request Free Sample Report Pulmonary drugs are the medications which are indicated for the treatment of several types of pulmonary disease such as asthma, pneumonia, allergic rhinitis, pulmonary hypertension, and others.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. The global pulmonary drug market is primarily driven by increasing incidence of chronic respiratory diseases, tobacco smoking, and government & non-government initiatives. Other factors like the increase in disposable income, rise in investments for R&D, and increasing healthcare spending are opportunities driving the global pulmonary drugs market. Also, the entrance of innovative and effective drugs in the pulmonary drugs market and substantial investments in the emerging of respiratory drug delivery systems is expected to drive the future of the market. On the other hand, the availability of counterfeit drugs, patent expiry of drugs, and increasing manufactures of generic medicines in the pulmonary drugs market might hamper the growth. Based on the drug classes, the combination drugs segment holds the largest market share as it is comparatively nontoxic than the other drugs and key companies face no competition from generic alternatives. Additionally, the emergence of advanced and inexpensive drug delivery systems and the advent of triple combination drugs are expected to stimulate the market segment throughout the forecast period. Region-wise, North America has the dominant share in the global pulmonary drugs market and can be attributed to the growing number of respiratory diseases in the region. According to the Centers for Disease Control and Prevention (CDC), 2018, the number of adults aged 18 and over who currently have asthma in the U.S. are 19.10 million. Also, the Asia-Pacific region is expected to be the fastest-growing market throughout the forecast period, thanks to the rapidly improving healthcare infrastructure and the presence of a broad base of the target population. The rise of disposable income and their growing expenditure on healthcare boost the pulmonary drug market in the Asia Pacific region. The report covers recent development of the market for pulmonary drugs such as January 2019, the U.S. Food and Drug Administration approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older in patients with COPD. The objective of the report is to present comprehensive analysis of global pulmonary drugs market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding global pulmonary drugs market dynamics, structure by analyzing the market segments, and project the global pulmonary drugs market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the global pulmonary drugs market make the report investor’s guide.

Scope of the Global Pulmonary Drugs Market: Inquire before buying

Global Pulmonary Drugs Market, By Drug Class

• Inhaled Corticosteroids (ICS) • Long-Acting Beta2-Agonists (LABA) • Antihistamines • Vasodilators • Short-Acting Beta2-Agonists (SABA) • Anticholinergics • Combination Drugs • Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)

Global Pulmonary Drugs Market, By Application

• Asthma & COPD • Allergic Rhinitis • Pulmonary Arterial Hypertension • Cystic Fibrosis • Others

Global Pulmonary Drugs Market, By Distribution Channel

• Hospital Pharmacies • Retail Pharmacies • Drug Stores • E-commerce

Global Pulmonary Drugs Market, By Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America

Key players operating in Global Pulmonary Drugs Market

• Sunovion Pharmaceuticals Inc. • AstraZeneca • Novartis AG • F. Hoffmann-La Roche Ltd • GlaxoSmithKline plc. • Teva Pharmaceutical Industries Ltd. • Merck Sharp & Dohme Corp • Boehringer Ingelheim International GmbH. • Actelion Pharmaceuticals Ltd • Bayer AG • Sanofi SA • Meda Pharmaceuticals • Circassia Pharmaceuticals Plc. • Mallinckrodt Pharmaceuticals Plc. • Cheisi Farmaceutici S.p.A • Zambon Company S.p.A • Alaxia SAS
Global Pulmonary Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Pulmonary Drugs Market, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Antihistamines Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Pulmonary Drugs Market Analysis and Forecast 6.1. Global Pulmonary Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Pulmonary Drugs Market Analysis and Forecast, By Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Pulmonary Drugs Market Value Share Analysis, By Drug Class 7.4. Global Pulmonary Drugs Market Size (US$ Bn) Forecast, By Drug Class 7.5. Global Pulmonary Drugs Market Analysis, By Drug Class 7.6. Global Pulmonary Drugs Market Attractiveness Analysis, By Drug Class 8. Global Pulmonary Drugs Market Analysis and Forecast, By Application 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Pulmonary Drugs Market Value Share Analysis, By Application 8.4. Global Pulmonary Drugs Market Size (US$ Bn) Forecast, By Application 8.5. Global Pulmonary Drugs Market Analysis, By Application 8.6. Global Pulmonary Drugs Market Attractiveness Analysis, By Application 9. Global Pulmonary Drugs Market Analysis and Forecast, By Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Pulmonary Drugs Market Value Share Analysis, By Distribution Channel 9.4. Global Pulmonary Drugs Market Size (US$ Bn) Forecast, By Distribution Channel 9.5. Global Pulmonary Drugs Market Analysis, By Distribution Channel 9.6. Global Pulmonary Drugs Market Attractiveness Analysis, By Distribution Channel 10. Global Pulmonary Drugs Market Analysis, by Region 10.1. Global Pulmonary Drugs Market Value Share Analysis, by Region 10.2. Global Pulmonary Drugs Market Size (US$ Bn) Forecast, by Region 10.3. Global Pulmonary Drugs Market Attractiveness Analysis, by Region 11. North America Pulmonary Drugs Market Analysis 11.1. Key Findings 11.2. North America Pulmonary Drugs Market Overview 11.3. North America Pulmonary Drugs Market Value Share Analysis, By Drug Class 11.4. North America Pulmonary Drugs Market Forecast, By Drug Class 11.4.1. Inhaled Corticosteroids (ICS) 11.4.2. Long-Acting Beta2-Agonists (LABA) 11.4.3. Antihistamines 11.4.4. Vasodilators 11.4.5. Short-Acting Beta2-Agonists (SABA) 11.4.6. Anticholinergics 11.4.7. Combination Drugs 11.4.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 11.5. North America Pulmonary Drugs Market Value Share Analysis, By Application 11.6. North America Pulmonary Drugs Market Forecast, By Application 11.6.1. Asthma & COPD 11.6.2. Allergic Rhinitis 11.6.3. Pulmonary Arterial Hypertension 11.6.4. Cystic Fibrosis 11.6.5. Others 11.7. North America Pulmonary Drugs Market Value Share Analysis, By Distribution Channel 11.8. North America Pulmonary Drugs Market Forecast, By Distribution Channel 11.8.1. Hospital Pharmacies 11.8.2. Retail Pharmacies 11.8.3. Drug Stores 11.8.4. E-commerce 11.9. North America Pulmonary Drugs Market Value Share Analysis, by Country 11.10. North America Pulmonary Drugs Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Pulmonary Drugs Market Analysis, by Country 11.12. U.S. Pulmonary Drugs Market Forecast, By Drug Class 11.12.1. Inhaled Corticosteroids (ICS) 11.12.2. Long-Acting Beta2-Agonists (LABA) 11.12.3. Antihistamines 11.12.4. Vasodilators 11.12.5. Short-Acting Beta2-Agonists (SABA) 11.12.6. Anticholinergics 11.12.7. Combination Drugs 11.12.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 11.13. U.S. Pulmonary Drugs Market Forecast, By Application 11.13.1. Asthma & COPD 11.13.2. Allergic Rhinitis 11.13.3. Pulmonary Arterial Hypertension 11.13.4. Cystic Fibrosis 11.13.5. Others 11.14. U.S. Pulmonary Drugs Market Forecast, By Distribution Channel 11.14.1. Hospital Pharmacies 11.14.2. Retail Pharmacies 11.14.3. Drug Stores 11.14.4. E-commerce 11.15. Canada Pulmonary Drugs Market Forecast, By Drug Class 11.15.1. Inhaled Corticosteroids (ICS) 11.15.2. Long-Acting Beta2-Agonists (LABA) 11.15.3. Antihistamines 11.15.4. Vasodilators 11.15.5. Short-Acting Beta2-Agonists (SABA) 11.15.6. Anticholinergics 11.15.7. Combination Drugs 11.15.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 11.16. Canada Pulmonary Drugs Market Forecast, By Application 11.16.1. Asthma & COPD 11.16.2. Allergic Rhinitis 11.16.3. Pulmonary Arterial Hypertension 11.16.4. Cystic Fibrosis 11.16.5. Others 11.17. Canada Pulmonary Drugs Market Forecast, By Distribution Channel 11.17.1. Hospital Pharmacies 11.17.2. Retail Pharmacies 11.17.3. Drug Stores 11.17.4. E-commerce 11.18. North America Pulmonary Drugs Market Attractiveness Analysis 11.18.1. By Drug Class 11.18.2. By Application 11.18.3. By Distribution Channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Development 12. Europe Pulmonary Drugs Market Analysis 12.1. Key Findings 12.2. Europe Pulmonary Drugs Market Overview 12.3. Europe Pulmonary Drugs Market Value Share Analysis, By Drug Class 12.4. Europe Pulmonary Drugs Market Forecast, By Drug Class 12.4.1. Inhaled Corticosteroids (ICS) 12.4.2. Long-Acting Beta2-Agonists (LABA) 12.4.3. Antihistamines 12.4.4. Vasodilators 12.4.5. Short-Acting Beta2-Agonists (SABA) 12.4.6. Anticholinergics 12.4.7. Combination Drugs 12.4.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 12.5. Europe Pulmonary Drugs Market Value Share Analysis, By Application 12.6. Europe Pulmonary Drugs Market Forecast, By Application 12.6.1. Asthma & COPD 12.6.2. Allergic Rhinitis 12.6.3. Pulmonary Arterial Hypertension 12.6.4. Cystic Fibrosis 12.6.5. Others 12.7. Europe Pulmonary Drugs Market Value Share Analysis, By Distribution Channel 12.8. Europe Pulmonary Drugs Market Forecast, By Distribution Channel 12.8.1. Hospital Pharmacies 12.8.2. Retail Pharmacies 12.8.3. Drug Stores 12.8.4. E-commerce 12.9. Europe Pulmonary Drugs Market Value Share Analysis, by Country 12.10. Europe Pulmonary Drugs Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Pulmonary Drugs Market Analysis, by Country 12.12. Germany Pulmonary Drugs Market Forecast, By Drug Class 12.12.1. Inhaled Corticosteroids (ICS) 12.12.2. Long-Acting Beta2-Agonists (LABA) 12.12.3. Antihistamines 12.12.4. Vasodilators 12.12.5. Short-Acting Beta2-Agonists (SABA) 12.12.6. Anticholinergics 12.12.7. Combination Drugs 12.12.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 12.13. Germany Pulmonary Drugs Market Forecast, By Application 12.13.1. Asthma & COPD 12.13.2. Allergic Rhinitis 12.13.3. Pulmonary Arterial Hypertension 12.13.4. Cystic Fibrosis 12.13.5. Others 12.14. Germany Pulmonary Drugs Market Forecast, By Distribution Channel 12.14.1. Hospital Pharmacies 12.14.2. Retail Pharmacies 12.14.3. Drug Stores 12.14.4. E-commerce 12.15. U.K. Pulmonary Drugs Market Forecast, By Drug Class 12.15.1. Inhaled Corticosteroids (ICS) 12.15.2. Long-Acting Beta2-Agonists (LABA) 12.15.3. Antihistamines 12.15.4. Vasodilators 12.15.5. Short-Acting Beta2-Agonists (SABA) 12.15.6. Anticholinergics 12.15.7. Combination Drugs 12.15.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 12.16. U.K. Pulmonary Drugs Market Forecast, By Application 12.16.1. Asthma & COPD 12.16.2. Allergic Rhinitis 12.16.3. Pulmonary Arterial Hypertension 12.16.4. Cystic Fibrosis 12.16.5. Others 12.17. U.K. Pulmonary Drugs Market Forecast, By Distribution Channel 12.17.1. Hospital Pharmacies 12.17.2. Retail Pharmacies 12.17.3. Drug Stores 12.17.4. E-commerce 12.18. France Pulmonary Drugs Market Forecast, By Drug Class 12.18.1. Inhaled Corticosteroids (ICS) 12.18.2. Long-Acting Beta2-Agonists (LABA) 12.18.3. Antihistamines 12.18.4. Vasodilators 12.18.5. Short-Acting Beta2-Agonists (SABA) 12.18.6. Anticholinergics 12.18.7. Combination Drugs 12.18.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 12.19. France Pulmonary Drugs Market Forecast, By Application 12.19.1. Asthma & COPD 12.19.2. Allergic Rhinitis 12.19.3. Pulmonary Arterial Hypertension 12.19.4. Cystic Fibrosis 12.19.5. Others 12.20. France Pulmonary Drugs Market Forecast, By Distribution Channel 12.20.1. Hospital Pharmacies 12.20.2. Retail Pharmacies 12.20.3. Drug Stores 12.20.4. E-commerce 12.21. Italy Pulmonary Drugs Market Forecast, By Drug Class 12.21.1. Inhaled Corticosteroids (ICS) 12.21.2. Long-Acting Beta2-Agonists (LABA) 12.21.3. Antihistamines 12.21.4. Vasodilators 12.21.5. Short-Acting Beta2-Agonists (SABA) 12.21.6. Anticholinergics 12.21.7. Combination Drugs 12.21.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 12.22. Italy Pulmonary Drugs Market Forecast, By Application 12.22.1. Asthma & COPD 12.22.2. Allergic Rhinitis 12.22.3. Pulmonary Arterial Hypertension 12.22.4. Cystic Fibrosis 12.22.5. Others 12.23. Italy Pulmonary Drugs Market Forecast, By Distribution Channel 12.23.1. Hospital Pharmacies 12.23.2. Retail Pharmacies 12.23.3. Drug Stores 12.23.4. E-commerce 12.24. Spain Pulmonary Drugs Market Forecast, By Drug Class 12.24.1. Inhaled Corticosteroids (ICS) 12.24.2. Long-Acting Beta2-Agonists (LABA) 12.24.3. Antihistamines 12.24.4. Vasodilators 12.24.5. Short-Acting Beta2-Agonists (SABA) 12.24.6. Anticholinergics 12.24.7. Combination Drugs 12.24.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 12.25. Spain Pulmonary Drugs Market Forecast, By Application 12.25.1. Asthma & COPD 12.25.2. Allergic Rhinitis 12.25.3. Pulmonary Arterial Hypertension 12.25.4. Cystic Fibrosis 12.25.5. Others 12.26. Spain Pulmonary Drugs Market Forecast, By Distribution Channel 12.26.1. Hospital Pharmacies 12.26.2. Retail Pharmacies 12.26.3. Drug Stores 12.26.4. E-commerce 12.27. Rest of Europe Pulmonary Drugs Market Forecast, By Drug Class 12.27.1. Inhaled Corticosteroids (ICS) 12.27.2. Long-Acting Beta2-Agonists (LABA) 12.27.3. Antihistamines 12.27.4. Vasodilators 12.27.5. Short-Acting Beta2-Agonists (SABA) 12.27.6. Anticholinergics 12.27.7. Combination Drugs 12.27.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 12.28. Rest of Europe Pulmonary Drugs Market Forecast, By Application 12.28.1. Asthma & COPD 12.28.2. Allergic Rhinitis 12.28.3. Pulmonary Arterial Hypertension 12.28.4. Cystic Fibrosis 12.28.5. Others 12.29. Rest of Europe Pulmonary Drugs Market Forecast, By Distribution Channel 12.29.1. Hospital Pharmacies 12.29.2. Retail Pharmacies 12.29.3. Drug Stores 12.29.4. E-commerce 12.30. Europe Pulmonary Drugs Market Attractiveness Analysis 12.30.1. By Drug Class 12.30.2. By Application 12.30.3. By Distribution Channel 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Development 13. Asia Pacific Pulmonary Drugs Market Analysis 13.1. Key Findings 13.2. Asia Pacific Pulmonary Drugs Market Overview 13.3. Asia Pacific Pulmonary Drugs Market Value Share Analysis, By Drug Class 13.4. Asia Pacific Pulmonary Drugs Market Forecast, By Drug Class 13.4.1. Inhaled Corticosteroids (ICS) 13.4.2. Long-Acting Beta2-Agonists (LABA) 13.4.3. Antihistamines 13.4.4. Vasodilators 13.4.5. Short-Acting Beta2-Agonists (SABA) 13.4.6. Anticholinergics 13.4.7. Combination Drugs 13.4.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 13.5. Asia Pacific Pulmonary Drugs Market Value Share Analysis, By Application 13.6. Asia Pacific Pulmonary Drugs Market Forecast, By Application 13.6.1. Asthma & COPD 13.6.2. Allergic Rhinitis 13.6.3. Pulmonary Arterial Hypertension 13.6.4. Cystic Fibrosis 13.6.5. Others 13.7. Asia Pacific Pulmonary Drugs Market Value Share Analysis, By Distribution Channel 13.8. Asia Pacific Pulmonary Drugs Market Forecast, By Distribution Channel 13.8.1. Hospital Pharmacies 13.8.2. Retail Pharmacies 13.8.3. Drug Stores 13.8.4. E-commerce 13.9. Asia Pacific Pulmonary Drugs Market Value Share Analysis, by Country 13.10. Asia Pacific Pulmonary Drugs Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Pulmonary Drugs Market Analysis, by Country 13.12. China Pulmonary Drugs Market Forecast, By Drug Class 13.12.1. Inhaled Corticosteroids (ICS) 13.12.2. Long-Acting Beta2-Agonists (LABA) 13.12.3. Antihistamines 13.12.4. Vasodilators 13.12.5. Short-Acting Beta2-Agonists (SABA) 13.12.6. Anticholinergics 13.12.7. Combination Drugs 13.12.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 13.13. China Pulmonary Drugs Market Forecast, By Application 13.13.1. Asthma & COPD 13.13.2. Allergic Rhinitis 13.13.3. Pulmonary Arterial Hypertension 13.13.4. Cystic Fibrosis 13.13.5. Others 13.14. China Pulmonary Drugs Market Forecast, By Distribution Channel 13.14.1. Hospital Pharmacies 13.14.2. Retail Pharmacies 13.14.3. Drug Stores 13.14.4. E-commerce 13.15. India Pulmonary Drugs Market Forecast, By Drug Class 13.15.1. Inhaled Corticosteroids (ICS) 13.15.2. Long-Acting Beta2-Agonists (LABA) 13.15.3. Antihistamines 13.15.4. Vasodilators 13.15.5. Short-Acting Beta2-Agonists (SABA) 13.15.6. Anticholinergics 13.15.7. Combination Drugs 13.15.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 13.16. India Pulmonary Drugs Market Forecast, By Application 13.16.1. Asthma & COPD 13.16.2. Allergic Rhinitis 13.16.3. Pulmonary Arterial Hypertension 13.16.4. Cystic Fibrosis 13.16.5. Others 13.17. India Pulmonary Drugs Market Forecast, By Distribution Channel 13.17.1. Hospital Pharmacies 13.17.2. Retail Pharmacies 13.17.3. Drug Stores 13.17.4. E-commerce 13.18. Japan Pulmonary Drugs Market Forecast, By Drug Class 13.18.1. Inhaled Corticosteroids (ICS) 13.18.2. Long-Acting Beta2-Agonists (LABA) 13.18.3. Antihistamines 13.18.4. Vasodilators 13.18.5. Short-Acting Beta2-Agonists (SABA) 13.18.6. Anticholinergics 13.18.7. Combination Drugs 13.18.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 13.19. Japan Pulmonary Drugs Market Forecast, By Application 13.19.1. Asthma & COPD 13.19.2. Allergic Rhinitis 13.19.3. Pulmonary Arterial Hypertension 13.19.4. Cystic Fibrosis 13.19.5. Others 13.20. Japan Pulmonary Drugs Market Forecast, By Distribution Channel 13.20.1. Hospital Pharmacies 13.20.2. Retail Pharmacies 13.20.3. Drug Stores 13.20.4. E-commerce 13.21. ASEAN Pulmonary Drugs Market Forecast, By Drug Class 13.21.1. Inhaled Corticosteroids (ICS) 13.21.2. Long-Acting Beta2-Agonists (LABA) 13.21.3. Antihistamines 13.21.4. Vasodilators 13.21.5. Short-Acting Beta2-Agonists (SABA) 13.21.6. Anticholinergics 13.21.7. Combination Drugs 13.21.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 13.22. ASEAN Pulmonary Drugs Market Forecast, By Application 13.22.1. Asthma & COPD 13.22.2. Allergic Rhinitis 13.22.3. Pulmonary Arterial Hypertension 13.22.4. Cystic Fibrosis 13.22.5. Others 13.23. ASEAN Pulmonary Drugs Market Forecast, By Distribution Channel 13.23.1. Hospital Pharmacies 13.23.2. Retail Pharmacies 13.23.3. Drug Stores 13.23.4. E-commerce 13.24. Rest of Asia Pacific Pulmonary Drugs Market Forecast, By Drug Class 13.24.1. Inhaled Corticosteroids (ICS) 13.24.2. Long-Acting Beta2-Agonists (LABA) 13.24.3. Antihistamines 13.24.4. Vasodilators 13.24.5. Short-Acting Beta2-Agonists (SABA) 13.24.6. Anticholinergics 13.24.7. Combination Drugs 13.24.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 13.25. Rest of Asia Pacific Pulmonary Drugs Market Forecast, By Application 13.25.1. Asthma & COPD 13.25.2. Allergic Rhinitis 13.25.3. Pulmonary Arterial Hypertension 13.25.4. Cystic Fibrosis 13.25.5. Others 13.26. Rest of Asia Pacific Pulmonary Drugs Market Forecast, By Distribution Channel 13.26.1. Hospital Pharmacies 13.26.2. Retail Pharmacies 13.26.3. Drug Stores 13.26.4. E-commerce 13.27. Asia Pacific Pulmonary Drugs Market Attractiveness Analysis 13.27.1. By Drug Class 13.27.2. By Application 13.27.3. By Distribution Channel 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Development 14. Middle East & Africa Pulmonary Drugs Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Pulmonary Drugs Market Overview 14.3. Middle East & Africa Pulmonary Drugs Market Value Share Analysis, By Drug Class 14.4. Middle East & Africa Pulmonary Drugs Market Forecast, By Drug Class 14.4.1. Inhaled Corticosteroids (ICS) 14.4.2. Long-Acting Beta2-Agonists (LABA) 14.4.3. Antihistamines 14.4.4. Vasodilators 14.4.5. Short-Acting Beta2-Agonists (SABA) 14.4.6. Anticholinergics 14.4.7. Combination Drugs 14.4.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 14.5. Middle East & Africa Pulmonary Drugs Market Value Share Analysis, By Application 14.6. Middle East & Africa Pulmonary Drugs Market Forecast, By Application 14.6.1. Asthma & COPD 14.6.2. Allergic Rhinitis 14.6.3. Pulmonary Arterial Hypertension 14.6.4. Cystic Fibrosis 14.6.5. Others 14.7. Middle East & Africa Pulmonary Drugs Market Value Share Analysis, By Distribution Channel 14.8. Middle East & Africa Pulmonary Drugs Market Forecast, By Distribution Channel 14.8.1. Hospital Pharmacies 14.8.2. Retail Pharmacies 14.8.3. Drug Stores 14.8.4. E-commerce 14.9. Middle East & Africa Pulmonary Drugs Market Value Share Analysis, by Country 14.10. Middle East & Africa Pulmonary Drugs Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Pulmonary Drugs Market Analysis, by Country 14.12. GCC Pulmonary Drugs Market Forecast, By Drug Class 14.12.1. Inhaled Corticosteroids (ICS) 14.12.2. Long-Acting Beta2-Agonists (LABA) 14.12.3. Antihistamines 14.12.4. Vasodilators 14.12.5. Short-Acting Beta2-Agonists (SABA) 14.12.6. Anticholinergics 14.12.7. Combination Drugs 14.12.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 14.13. GCC Pulmonary Drugs Market Forecast, By Application 14.13.1. Asthma & COPD 14.13.2. Allergic Rhinitis 14.13.3. Pulmonary Arterial Hypertension 14.13.4. Cystic Fibrosis 14.13.5. Others 14.14. GCC Pulmonary Drugs Market Forecast, By Distribution Channel 14.14.1. Hospital Pharmacies 14.14.2. Retail Pharmacies 14.14.3. Drug Stores 14.14.4. E-commerce 14.15. South Africa Pulmonary Drugs Market Forecast, By Drug Class 14.15.1. Inhaled Corticosteroids (ICS) 14.15.2. Long-Acting Beta2-Agonists (LABA) 14.15.3. Antihistamines 14.15.4. Vasodilators 14.15.5. Short-Acting Beta2-Agonists (SABA) 14.15.6. Anticholinergics 14.15.7. Combination Drugs 14.15.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 14.16. South Africa Pulmonary Drugs Market Forecast, By Application 14.16.1. Asthma & COPD 14.16.2. Allergic Rhinitis 14.16.3. Pulmonary Arterial Hypertension 14.16.4. Cystic Fibrosis 14.16.5. Others 14.17. South Africa Pulmonary Drugs Market Forecast, By Distribution Channel 14.17.1. Hospital Pharmacies 14.17.2. Retail Pharmacies 14.17.3. Drug Stores 14.17.4. E-commerce 14.18. Rest of Middle East & Africa Pulmonary Drugs Market Forecast, By Drug Class 14.18.1. Inhaled Corticosteroids (ICS) 14.18.2. Long-Acting Beta2-Agonists (LABA) 14.18.3. Antihistamines 14.18.4. Vasodilators 14.18.5. Short-Acting Beta2-Agonists (SABA) 14.18.6. Anticholinergics 14.18.7. Combination Drugs 14.18.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 14.19. Rest of Middle East & Africa Pulmonary Drugs Market Forecast, By Application 14.19.1. Asthma & COPD 14.19.2. Allergic Rhinitis 14.19.3. Pulmonary Arterial Hypertension 14.19.4. Cystic Fibrosis 14.19.5. Others 14.20. Rest of Middle East & Africa Pulmonary Drugs Market Forecast, By Distribution Channel 14.20.1. Hospital Pharmacies 14.20.2. Retail Pharmacies 14.20.3. Drug Stores 14.20.4. E-commerce 14.21. Middle East & Africa Pulmonary Drugs Market Attractiveness Analysis 14.21.1. By Drug Class 14.21.2. By Application 14.21.3. By Distribution Channel 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Development 15. South America Pulmonary Drugs Market Analysis 15.1. Key Findings 15.2. South America Pulmonary Drugs Market Overview 15.3. South America Pulmonary Drugs Market Value Share Analysis, By Drug Class 15.4. South America Pulmonary Drugs Market Forecast, By Drug Class 15.4.1. Inhaled Corticosteroids (ICS) 15.4.2. Long-Acting Beta2-Agonists (LABA) 15.4.3. Antihistamines 15.4.4. Vasodilators 15.4.5. Short-Acting Beta2-Agonists (SABA) 15.4.6. Anticholinergics 15.4.7. Combination Drugs 15.4.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 15.5. South America Pulmonary Drugs Market Value Share Analysis, By Application 15.6. South America Pulmonary Drugs Market Forecast, By Application 15.6.1. Asthma & COPD 15.6.2. Allergic Rhinitis 15.6.3. Pulmonary Arterial Hypertension 15.6.4. Cystic Fibrosis 15.6.5. Others 15.7. South America Pulmonary Drugs Market Value Share Analysis, By Distribution Channel 15.8. South America Pulmonary Drugs Market Forecast, By Distribution Channel 15.8.1. Hospital Pharmacies 15.8.2. Retail Pharmacies 15.8.3. Drug Stores 15.8.4. E-commerce 15.9. South America Pulmonary Drugs Market Value Share Analysis, by Country 15.10. South America Pulmonary Drugs Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Pulmonary Drugs Market Analysis, by Country 15.12. Brazil Pulmonary Drugs Market Forecast, By Drug Class 15.12.1. Inhaled Corticosteroids (ICS) 15.12.2. Long-Acting Beta2-Agonists (LABA) 15.12.3. Antihistamines 15.12.4. Vasodilators 15.12.5. Short-Acting Beta2-Agonists (SABA) 15.12.6. Anticholinergics 15.12.7. Combination Drugs 15.12.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 15.13. Brazil Pulmonary Drugs Market Forecast, By Application 15.13.1. Asthma & COPD 15.13.2. Allergic Rhinitis 15.13.3. Pulmonary Arterial Hypertension 15.13.4. Cystic Fibrosis 15.13.5. Others 15.14. Brazil Pulmonary Drugs Market Forecast, By Distribution Channel 15.14.1. Hospital Pharmacies 15.14.2. Retail Pharmacies 15.14.3. Drug Stores 15.14.4. E-commerce 15.15. Mexico Pulmonary Drugs Market Forecast, By Drug Class 15.15.1. Inhaled Corticosteroids (ICS) 15.15.2. Long-Acting Beta2-Agonists (LABA) 15.15.3. Antihistamines 15.15.4. Vasodilators 15.15.5. Short-Acting Beta2-Agonists (SABA) 15.15.6. Anticholinergics 15.15.7. Combination Drugs 15.15.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 15.16. Mexico Pulmonary Drugs Market Forecast, By Application 15.16.1. Asthma & COPD 15.16.2. Allergic Rhinitis 15.16.3. Pulmonary Arterial Hypertension 15.16.4. Cystic Fibrosis 15.16.5. Others 15.17. Mexico Pulmonary Drugs Market Forecast, By Distribution Channel 15.17.1. Hospital Pharmacies 15.17.2. Retail Pharmacies 15.17.3. Drug Stores 15.17.4. E-commerce 15.18. Rest of South America Pulmonary Drugs Market Forecast, By Drug Class 15.18.1. Inhaled Corticosteroids (ICS) 15.18.2. Long-Acting Beta2-Agonists (LABA) 15.18.3. Antihistamines 15.18.4. Vasodilators 15.18.5. Short-Acting Beta2-Agonists (SABA) 15.18.6. Anticholinergics 15.18.7. Combination Drugs 15.18.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) 15.19. Rest of South America Pulmonary Drugs Market Forecast, By Application 15.19.1. Asthma & COPD 15.19.2. Allergic Rhinitis 15.19.3. Pulmonary Arterial Hypertension 15.19.4. Cystic Fibrosis 15.19.5. Others 15.20. Rest of South America Pulmonary Drugs Market Forecast, By Distribution Channel 15.20.1. Hospital Pharmacies 15.20.2. Retail Pharmacies 15.20.3. Drug Stores 15.20.4. E-commerce 15.21. South America Pulmonary Drugs Market Attractiveness Analysis 15.21.1. By Drug Class 15.21.2. By Application 15.21.3. By Distribution Channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Development 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Sunovion Pharmaceuticals Inc. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Company Footprint 16.3.2. AstraZeneca 16.3.3. Novartis AG 16.3.4. F. Hoffmann-La Roche Ltd 16.3.5. GlaxoSmithKline plc. 16.3.6. Teva Pharmaceutical Industries Ltd. 16.3.7. Merck Sharp & Dohme Corp 16.3.8. Boehringer Ingelheim International GmbH. 16.3.9. Actelion Pharmaceuticals Ltd 16.3.10. Bayer AG 16.3.11. Sanofi SA 16.3.12. Meda Pharmaceuticals 16.3.13. Circassia Pharmaceuticals Plc. 16.3.14. Mallinckrodt Pharmaceuticals Plc. 16.3.15. Cheisi Farmaceutici S.p.A 16.3.16. Zambon Company S.p.A 16.3.17. Alaxia SAS 17. Primary Key Insights

About This Report

Report ID 37939
Category Healthcare
Published Date Nov 2019
Updated Date Oct 2020
Contact Us